Immune responses to baculovirus-displayed enterovirus 71 VP1 antigen

Expert Review of Vaccines

Volumn 12, Issue 4, 2013, Pages 357-364

  Kiener, Tanja K ^a   Premanand, Balraj ^a   Kwang, Jimmy ^a,b  

^a Animal Health Biotechnology   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

baculovirus surface display; cross neutralization; enterovirus 71; oral immunization; passive protection; shuttle promoter; transduction; VP1 subunit vaccine

Indexed keywords

BACULOVIRUS VECTOR; CIRCULAR DNA; CIRCUMSPOROZOITE PROTEIN; HEMAGGLUTININ; POLYHEDRIN; PROTEIN VP1; PROTEIN VP28; SIALIDASE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CRYSTAL STRUCTURE; ENTEROVIRUS 71; GENE EXPRESSION SYSTEM; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; MAMMAL CELL; NONHUMAN; PASSIVE IMMUNIZATION; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; VIRAL GENE DELIVERY SYSTEM; VIRUS NEUTRALIZATION;

ASIA; BACULOVIRIDAE; CHILD, PRESCHOOL; DRUG DELIVERY SYSTEMS; ENTEROVIRUS A, HUMAN; ENTEROVIRUS INFECTIONS; HUMANS; VACCINATION; VACCINES, SUBUNIT; VACCINES, SYNTHETIC; VIRAL STRUCTURAL PROTEINS; VIRAL VACCINES;

EID: 84875918879     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.13.18     Document Type: Article

References (56)

1. Qiu J. Enterovirus 71 infection: a new threat to global public health? Lancet Neurol. 7(10), 868-869 (2008).
2. Xu W, Liu CF, Yan L et al. Distribution of enteroviruses in hospitalized children with hand, foot and mouth disease and relationship between pathogens and nervous system complications. Virol J. 9(1)
3. Ooi MH, Wong SC, Podin Y et al. Human enterovirus 71 disease in Sarawak, Malaysia: a prospective clinical, virological, and molecular epidemiological study. Clin. Infect. Dis. 44(5), 646-656 (2007).
4. Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect. Dis. 10(11), 778-790 (2010).
5. Tee KK, Lam TT, Chan YF et al. Evolutionary genetics of human enterovirus 71: origin, population dynamics, natural selection, and seasonal periodicity of the VP1 gene. J. Virol. 84(7), 3339-3350 (2010).
6. Plevka P, Perera R, Cardosa J, Kuhn RJ, Rossmann MG. Crystal structure of human enterovirus 71. Science 336(6086)
7. Wang X, Peng W, Ren J et al. A sensoradaptor mechanism for enterovirus uncoating from structures of EV71. Nat. Struct. Mol. Biol. 19(4), 424-429 (2012).
8. Kiener TK, Jia Q, Lim XF et al. Characterization and specificity of the linear epitope of the enterovirus 71 VP2 protein. Virol. J. 9, 55 (2012).
9. Foo DG, Alonso S, Phoon MC, Ramachandran NP, Chow VT, Poh CL. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res. 125(1), 61-68 (2007). (Pubitemid 46413387)
10. Lim XF, Jia Q, Khong WX et al. Characterization of an isotype-dependent monoclonal antibody against linear neutralizing epitope effective for prophylaxis of enterovirus 71 infection. PLoS ONE 7(1), e29751 (2012).
11. Li YP, Liang ZL, Gao Q et al. Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial. Vaccine 30(22), 3295-3303 (2012).
12. Zhu FC, Wang JZ, Li XL et al. Reactogenicity and immunogenicity of an enterovirus 71 vaccine in chinese healthy children and infants. Pediatr. Infect. Dis. J. 31(11), 1158-1165 (2012).
13. Meng FY, Li JX, Li XL et al. Tolerability and immunogenicity of an inactivated enterovirus 71 vaccine in Chinese healthy adults and children: an open label, Phase 1 clinical trial. Hum. Vaccin. Immunother. 8(5), 668-674 (2012).
14. Mena JA, Kamen AA. Insect cell technology is a versatile and robust vaccine manufacturing platform. Expert Rev. Vaccines 10(7), 1063-1081 (2011).
15. Teng CY, Chang SL, van Oers MM, Wu TY. Enhanced protein secretion from insect cells by co-expression of the chaperone calreticulin and translation initiation factor eIF4E. Mol. Biotechnol. (2012).
16. Kataoka C, Kaname Y, Taguwa S et al. Baculovirus GP64-mediated entry into mammalian cells. J. Virol. 86(5), 2610-2620 (2012).
17. Boyce FM, Bucher NL. Baculovirus-mediated gene transfer into mammalian cells. Proc. Natl Acad. Sci. USA 93(6), 2348-2352 (1996). (Pubitemid 26104353)
18. Fornwald JA, Lu Q, Wang D, Ames RS. Gene expression in mammalian cells using BacMam, a modified baculovirus system. Methods Mol. Biol. 388, 95-114 (2007). (Pubitemid 350189948)
19. He F, Ho Y, Yu L, Kwang J. WSSV ie1 promoter is more efficient than CMV promoter to express H5 hemagglutinin from influenza virus in baculovirus as a chicken vaccine. BMC Microbiol. 8, 238 (2008).
20. Sokolenko S, George S, Wagner A, Tuladhar A, Andrich JM, Aucoin MG. Co-expression vs. co-infection using baculovirus expression vectors in insect cell culture: Benefits and drawbacks. Biotechnol. Adv. 30(3), 766-781 (2012).
21. He F, Madhan S, Kwang J. Baculovirus vector as a delivery vehicle for influenza vaccines. Expert Rev. Vaccines 8(4), 455-467 (2009).
22. Treanor JJ, El Sahly H, King J et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine 29(44), 7733-7739 (2011).
23. Strauss R, Hüser A, Ni S et al. Baculovirusbased vaccination vectors allow for efficient induction of immune responses against plasmodium falciparum circumsporozoite protein. Mol. Ther. 15(1), 193-202 (2007). (Pubitemid 46043665)
24. Syed MS, Kwang J. Oral vaccination of baculovirus-expressed VP28 displays enhanced protection against white spot syndrome virus in Penaeus monodon. PLoS ONE 6(11), e26428 (2011).
25. Prabakaran M, Meng T, He F et al. Subcutaneous immunization with baculovirus surface-displayed hemagglutinin of pandemic H1N1 Influenza A virus induces protective immunity in mice. Clin. Vaccine Immunol. 18(9), 1582-1585 (2011).
26. Prabakaran M, Madhan S, Prabhu N, Qiang J, Kwang J. Gastrointestinal delivery of baculovirus displaying influenza virus hemagglutinin protects mice against heterologous H5N1 infection. J. Virol. 84(7), 3201-3209 (2010).
27. Grabherr R, Ernst W. Baculovirus for eukaryotic protein display. Curr. Gene Ther. 10(3), 195-200 (2010).
28. Jin R, Lv Z, Chen Q et al. Safety and immunogenicity of H5N1 influenza vaccine based on baculovirus surface display system of Bombyx mori. PLoS ONE 3(12), e3933 (2008).
29. Xu XG, Wang ZS, Zhang Q et al. Baculovirus surface display of E envelope glycoprotein of Japanese encephalitis virus and its immunogenicity of the displayed proteins in mouse and swine models. Vaccine 29(4), 636-643 (2011).
30. Suzuki T, Chang MO, Kitajima M, Takaku H. Baculovirus activates murine dendritic cells and induces non-specific NK cell and T cell immune responses. Cell. Immunol. 262(1), 35-43 (2010).
31. Transfiguracion J, Jorio H, Meghrous J, Jacob D, Kamen A. High yield purification of functional baculovirus vectors by size exclusion chromatography. J. Virol. Methods 142(1-2), 21-28 (2007). (Pubitemid 46590402)
32. Meng T, Kolpe AB, Kiener TK, Chow VT, Kwang J. Display of VP1 on the surface of baculovirus and its immunogenicity against heterologous human enterovirus 71 strains in mice. PLoS ONE 6(7), e21757 (2011).
33. Premanand B, Kiener TK, Meng T et al. Induction of protective immune responses against EV71 in mice by baculovirus encoding a novel expression cassette for capsid protein VP1. Antiviral Res. 95(3), 311-315 (2012).
34. Kolpe AB, Kiener TK, Grotenbreg GM, Kwang J. Display of enterovirus 71 VP1 on baculovirus as a type II transmembrane protein elicits protective B and T cell responses in immunized mice. Virus Res. 168(1-2), 64-72 (2012).
35. Gao H, Wang Y, Li N et al. Efficient gene delivery into mammalian cells mediated by a recombinant baculovirus containing a whispovirus ie1 promoter, a novel shuttle promoter between insect cells and mammalian cells. J. Biotechnol. 131(2), 138-143 (2007). (Pubitemid 47187507)
36. Prabakaran M, He F, Meng T et al. Neutralizing epitopes of influenza virus hemagglutinin: target for the development of a universal vaccine against H5N1 lineages. J. Virol. 84(22), 11822-11830 (2010).
37. Markusic DM, van Til NP, Hiralall JK, Elferink RP, Seppen J. Reduction of liver macrophage transduction by pseudotyping lentiviral vectors with a fusion envelope from Autographa californica GP64 and Sendai virus F2 domain. BMC Biotechnol. 9, 85 (2009).
38. Lin YH, Lee LH, Shih WL, Hu YC, Liu HJ. Baculovirus surface display of sigmaC and sigmaB proteins of avian reovirus and immunogenicity of the displayed proteins in a mouse model. Vaccine 26(50), 6361-6367 (2008).
39. Yang DG, Chung YC, Lai YK, Lai CW, Liu HJ, Hu YC. Avian influenza virus hemagglutinin display on baculovirus envelope: cytoplasmic domain affects virus properties and vaccine potential. Mol. Ther. 15(5), 989-996 (2007).
40. Borg J, Nevsten P, Wallenberg R et al. Amino-terminal anchored surface display in insect cells and budded baculovirus using the amino-terminal end of neuraminidase. J. Biotechnol. 114(1-2), 21-30 (2004). (Pubitemid 39298280)
41. Lin YW, Chang KC, Kao CM, Chang SP, Tung YY, Chen SH. Lymphocyte and antibody responses reduce enterovirus 71 lethality in mice by decreasing tissue viral loads. J. Virol. 83(13), 6477-6483 (2009).
42. Bek EJ, Hussain KM, Phuektes P et al. Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection. Vaccine 29(29-30), 4829-4838 (2011).
43. Dong C, Liu L, Zhao H et al. Immunoprotection elicited by an enterovirus type experimental inactivated vaccine in mice and rhesus monkeys. Vaccine 29(37), 6269-6275 (2011).
44. Ong KC, Devi S, Cardosa MJ, Wong KT. Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease. J. Virol. 84(1), 661-665 (2009).
45. Chong P, Guo MS, Lin FH, Hsiao KN, Weng SY et al. Immunological and biochemical characterization of coxsackie virus A16 viral particles. PLoS ONE 7(11), e49973 (2012).
46. Lee MS, Tseng FC, Wang JR, Chi CY, Chong P, Su IJ. Challenges to licensure of enterovirus 71 vaccines. PLoS Negl. Trop. Dis. 6(8), e1737 (2012).
47. Zhang Y, Zhu Z, Yang W et al. An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol. J. 7, 94 (2010).
48. Chou AH, Liu CC, Chang CP et al. Pilot scale production of highly efficacious and stable enterovirus 71 vaccine candidates. PLoS ONE 7(4), e34834 (2012).
49. Wong SS, Yip CC, Lau SK, Yuen KY. Human enterovirus 71 and hand, foot and mouth disease. Epidemiol. Infect. 138(8), 1071-1089 (2010).
50. Premanand B, Prabakaran M, Kiener TK, Kwang J. Recombinant baculovirus associated with bilosomes as an oral vaccine candidate against HEV71 infection in mice. PLoS ONE 8(2), e55536 (2013).
51. World Health Organization. www.who.int
52. Protein Sciences. www.proteinsciences.com
53. Organisation for Economic Co-operation and Development. www.oecd.org
54. European Commission. http://ec.europa.eu
55. FDA approves new vaccine for prevention of cervical cancer. www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/2009/ucm187048. htm
56. FDA approves new seasonal influenza vaccine made using novel technology. www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm335891.htm